
    
      The study duration is 24 weeks. Patients are treated with Testosterone Undecanoate 1000 mg/4
      ml, intramuscular (i.m.) or placebo at 0, 6 and 18 weeks.

      Outcome measures will be evaluated at 0 and 14 weeks.
    
  